Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme

Floyd, N.S.; Woo, Shiao Y.; Teh, Bin S.; Prado, Charlotte; Mai, W.; Trask, Todd; Gildenberg, Philip L.; Holoye, Paul Y.; Augspurger, Mark E.; Carpenter, L. Steven; Lu, Haiquan; Chiu, J. Kam; Grant, Walter H.; Butler, E. Brian

doi:10.1016/s0360-3016(03)01623-7

Cited by 122 publications

(97 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, median survival time amongst the five survivors in the present study was 23.3 months, which falls within the 2 -23 months period where RN is most likely observed [31]. For instance, Floyd, et al [38] reported survival of patients with brain necrosis at 23, 20, and nine months.…”

Section: Discussionsupporting

confidence: 45%

Innovative Hypofractionated Stereotactic Regimen Achieves Excellent Local Control With No Radiation Necrosis: Promising Results in the Management of Patients With Small Recurrent Inoperable GBM

Jia

Pannullo

Schwartz

et al. 2015

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 45%

Innovative Hypofractionated Stereotactic Regimen Achieves Excellent Local Control With No Radiation Necrosis: Promising Results in the Management of Patients With Small Recurrent Inoperable GBM

Jia

Pannullo

Schwartz

et al. 2015

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

“…Despite the increase of radiation induced necrosis incidence, the authors concluded that the treatment was safe and the outcomes comparable with standard practice (2). In several studies the incidence of late toxicity was greater with hypofractioned treatment regimen, specifi cally a 20% incidence of cerebral necrosis (17). In brachytherapy studies that pioneered hypofractioned treatment models, survival benefi ts have been reported but a greater incidence of radiation necrosis has been observed (18).…”

Section: Resultsmentioning

confidence: 99%

The Helical Tomotherapy Experience on Radiotherapy of Glioblastoma Multiforme

Küçüktülü¹

2018

Akd Med J

View full text Add to dashboard Cite

Objective: The standard treatment of Glioblastome Multiforme (GBM) is surgical resection followed by chemoradiotherapy and adjuvant temozolamide. Intensity Modulated Radiotherapy (IMRT) offer an advantage in terms of reducing the dose to critical normal structures and a reduced dose to the normal brain. It also offers application of Simultaneous Integrated Boost (SIB). Material and Methods:Among our 12 patients, 7 had a diagnosis of GBM whereas 3 of them were anaplastic oligoastrocytoma and 2 of them were diagnosed radiologically as high-grade glial tumor. In all patients, 60 Gy SIB-IMRT with concomitant Temozolomide was used. Results:In post treatment Magnetic Resonance Imaging (MRI), 8 patients had no recurrence whereas 2 patients showed partial response and in 2 patients there was no response at all. After a median follow-up period of 12 months, 3 patients survived disease free, and 9 patients were expired. The overall survival was 14.8 months. Median progression free survival was 4.4 months. The mean dose received by the brain stem was 12.90 Gy and 12.72 Gy for the optic chiasm. Conclusion:High doses can be given while protecting critical tissues with SIB-IMRT.

show abstract

“…Most importantly, hypofractionated RT would entail less frequent visits to the hospital, which could be of immense value in improving the QOL of these deeply distressed patients and their caregivers. The results of two recently reported phase II trials of hypofractionated Intensity Modulated Radiation Therapy (IMRT) are comparable with conventional fractionation and should provide further impetus to this form of treatment [50,51]. Despite the available evidence in the last three decades hypofractionated radiotherapy is still not accepted as a standard by the oncologic fraternity and remains investigational.…”

Section: Discussionmentioning

confidence: 99%

Modified optimal fractionation for poor prognosis malignant gliomas: An elusive search

Gupta

Dinshaw

2005

Acta Oncologica

View full text Add to dashboard Cite

The prognosis of malignant gliomas has not changed much over the last few decades despite refinements in neurosurgical techniques, high-precision radiotherapy, and newer chemotherapeutic agents. The median survival of poor prognosis malignant gliomas (older and/or poor performance status patients) still remains in the range of 6 Á/9 months following maximal safe resection and postoperative conventionally fractionated adjuvant radiotherapy with or without chemotherapy. However, six weeks of daily radiotherapy does seem inappropriate in relation to the short expected survival time in this subset and there is an increasing emphasis on reducing the overall treatment time and the number of hospital visits by such patients. This can be achieved either by accelerated radiotherapy or by hypofractionated radiation, both of which are equivalent to conventional fractionation in terms of palliative effect and survival, as in discussed in this review. Despite enough evidence, such alteration of fractionation has not gained widespread acceptance by the oncologic fraternity. This review has been conducted to collate the evidence that could help shift the paradigm from conventional to modified fractionation in poor prognosis malignant glioma patients.

show abstract

Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme

Cited by 122 publications

References 8 publications

Innovative Hypofractionated Stereotactic Regimen Achieves Excellent Local Control With No Radiation Necrosis: Promising Results in the Management of Patients With Small Recurrent Inoperable GBM

Innovative Hypofractionated Stereotactic Regimen Achieves Excellent Local Control With No Radiation Necrosis: Promising Results in the Management of Patients With Small Recurrent Inoperable GBM

The Helical Tomotherapy Experience on Radiotherapy of Glioblastoma Multiforme

Modified optimal fractionation for poor prognosis malignant gliomas: An elusive search

Contact Info

Product

Resources

About